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Abstract
Background: Malaria rapid diagnostic tests (RDTs) are increasingly used as a tool for the diagnosis of malaria, both
in endemic and in non-endemic settings. The present study reports the results of an external quality assessment
(EQA) session on RDTs in a non-endemic setting.
Methods: After validation of antigen stability during shipment at room temperature, three clinical samples and a
questionnaire were sent to clinical laboratories in Belgium and the Grand Duchy of Luxembourg using malaria
RDTs. Participants were asked to report the results of the RDTs as observations (visibility of the RDT control and
test lines) and interpretations (report as formulated to the clinician). In addition, participants were invited to fill in a
questionnaire on the place of RDTs in the diagnostic strategy of malaria.
Results: A total of 128/133 (96.2%) of clinical laboratories using RDTs participated. Six three-band and one four-
band RDT brands were used. Analytical errors were rare and included (i) not recognizing invalid RDT results (1.6%)
and (ii) missing the diagnosis of Plasmodium falciparum (0.8%). Minor errors were related to RDT test result
interpretation and included (i) reporting “RDT positive” without species identification in the case of P. falciparum
and non-falciparum species (16.9% and 6.5% respectively) and (ii) adding incorrect comments to the report (3.2%).
Some of these errors were related to incorrect RDT package insert instructions such as (i) not reporting the
possibility of mixed species infection in the case of P. falciparum and Plasmodium vivax (35.5% and 18.5%
respectively) and (ii) the interpretation of P. vivax instead of non-falciparum species at the presence of a pan-
species antigen line (4.0%). According to the questionnaire, 48.8% of participants processed ≤20 requests for
malaria diagnosis in 2009. During opening hours, 93.6% of 125 participants used RDTs as an adjunct to microscopy
but outside opening hours, nearly one third of 113 participants relied on RDTs as the primary (4.4%) or the single
tool (25.7%) for malaria diagnosis.
Conclusion: In this non-endemic setting, errors in RDT performance were mainly related to RDT test line
interpretations, partly due to incorrect package insert instructions. The reliance on RDTs as the primary or the
single tool for the diagnosis of malaria outside opening hours is of concern and should be avoided.
Background
Malaria rapid diagnostic tests (RDTs) are increasingly
used as a diagnostic tool in both malaria endemic and
non-endemic settings. RDTs detect Plasmodium para-
sites in blood by antibody-antigen reactions on a nitro-
cellulose strip, which become visible as cherry-red lines.
Different formats exist: two-band RDTs are mostly
designed to detect Plasmodium falciparum. They display
a control line and a test line, which targets either histi-
dine-rich protein-2 (HRP-2) or P. falciparum-specific
parasite lactate dehydrogenase (Pf-pLDH). Three- and
four-band RDTs display a control line and two or three
test lines, one targeting a P. falciparum specific antigen,
a second line targeting antigens common to the four
species, such as pan-Plasmodium-specific lactate parasite
dehydrogenase (pan-pLDH) or aldolase, and in case of
t h ef o u rb a n dR D T s ,at h i r dl i n ew h i c ht a r g e t sPlasmo-
dium vivax-specific pLDH (Pv-pLDH).
The use of RDTs is rapidly expanding: in 2007, more
than 70,000,000 tests were performed and more than 80
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endemic regions, RDTs are currently rolled out by
national malaria control programs as a tool for parasite
based diagnosis [1]. In non-endemic settings, where
microscopic expertise is lacking due to low incidence,
RDTs have been reported to perform accurately and
even better as compared to microscopy [2,3]. Despite
their robust design and their ease of use, RDTs are not
fail-proof and quality problems have been identified at
the level of production, transport and storage as well as
at the level of the end-user’s performance [4-10]. Initia-
tives for quality assurance along the route from design
to end-user have been inspired by the World Health
Organization (WHO). At the level of product perfor-
mance there have been the two evaluation rounds of
RDTs by WHO/Foundation for Innovative New Diag-
nostics (FIND) [11,12]. At the level of production and
distribution, WHO has set up a comprehensive quality
control strategy for production, transport and product
control in national reference laboratories as well as a lot
testing program [13,14]. With regard to the end-user’s
performance, there has been the redaction of generic
job aids [15,16] and the development of stable positive
controls [17]. Till now, external quality assessment
(EQA) sessions on the use of RDTs have not been orga-
nized. A national survey in the UK has, however, high-
lighted the need for such EQA sessions from the part of
clinical laboratories [18]. In light of these reasons, the
present EQA was organized.
Methods
Participants, samples and questionnaire
The present EQA session was organized among clinical
laboratories in Belgium and the Grand Duchy of Luxem-
bourg which had declared to be interested in EQA ses-
sions on malaria rapid diagnostic tests when subscribing
to the EQA session “Blood Parasites” or “Microbiology”
organized by the Institute of Public Health, Brussels,
B e l g i u m .I nas u r v e ya f t e r w a r d s ,t h en o n - s u b s c r i b i n g
laboratories were addressed to ask whether they use
RDTs or not in the diagnosis of malaria.
The EQA panel consisted of three samples of EDTA-
anticoagulated blood: one sample with P. falciparum,
another with no evidence of Plasmodium and a third
one with P. vivax (Table 1). They were obtained from
patients suspected of malaria presenting at the Institute
of Tropical Medicine (ITM). After initial analysis and
diagnosis, samples were stored at 4°C for a maximum of
48 hours and subsequently aliquoted in 150 μl-fractions
which were stored at -70°C. Total durations of storage
at -70°C till EQA shipment were 612, 249 and 240 days
for samples 1, 2 and 3 respectively.
Diagnosis of malaria, species identification and deter-
m i n a t i o no fp a r a s i t ed e n s i t yw e r ed o n eb ym i c r o s c o p y
and confirmed by PCR. According to standard practice
at ITM, thick and thin blood films were stained with
Giemsa (pH 8.0) and examined by light microscopy
using a × 500 magnification [19]. Parasite densities were
estimated by counting asexual parasites against 200
white blood cells (WBC) in thick blood films and con-
verting this number to parasites/μl using the actual
WBC count [8]. Parasite densities are further in this text
expressed as counts (of asexual parasites)/μl (of whole
blood), with 50,000 red blood cells/μls e ta s1 %o fr e d
blood cells [8]. Species identification was confirmed by
Plasmodium-specific PCR [20].
In addition to the samples, a questionnaire on the per-
formance of RDTs in clinical laboratories was prepared.
This questionnaire was based on a previous survey
p e r f o r m e di nt h eU K[ 1 8 ]a n da d d r e s s e di s s u e so ff r e -
quency of requests of malaria diagnosis, ease of use and
the place of RDTs in the diagnostic strategy.
Validation of shipment and questionnaire
For validation of the shipment at room temperature (in
particular the antigen stability), a try-out session was
performed among the members of the IPH referee com-
mittee, which consists of a panel of laboratory profes-
sionals in charge of piloting EQA sessions. Aliquots of
the samples at ITM were retrieved, allowed to thaw and
processed at room temperature. The samples were
tested against a panel of RDTs available in Belgium, as
listed in Table 2. Two of these brands were not available
at the time of try-out session (Cypress and Ultimed);
they were performed at the moment of the formal EQA
session. Aliquots were packaged according to the UN
3373 recommendations and transported the same day
by car to a regular IPH referee committee meeting dur-
ing which they were distributed: each member (n = 9)
received two packages, one for analysis by his/her
laboratory and another to be sent back by regular post
mail to ITM. The latter package contained a tempera-
ture logger (Escort data loggers®, Buchanan, Virginia
United States), making it possible to monitor the
Table 1 Clinical information and parasite density of the embedded samples of the EQA session
Sample number History Species, parasite density
1 Pregnant woman, Nigeria. P. falciparum, 53,024/μl=1 %
2 NGO volunteer, Burkina Faso, treated for malaria 4 weeks ago. No Plasmodium detected.
3 Traveler: Democratic Republic of the Congo, Haiti. P. vivax, 3,251/μl = 0.06%
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arrival at ITM, the returned packages with the samples
were stored at 4°C for a maximum of 48 hours and
RDT testing was repeated. The test line results observed
upon testing these returned aliquots were compared to
those that had been obtained in fresh samples.
All RDTs were performed according to the instruc-
tions of the manufacturer, except that the transfer
straws or loops supplied in the RDT kits were replaced
by a transfer pipette (Finnpipette, Helsinki, Finland).
Readings were carried out at daylight assisted by a stan-
dard electric bulb by two subsequent blinded observers,
and test line intensities were recorded [19]. RDT kits
had been stored between 18°C and 24°C before use.
Laboratory diagnosis of malaria at ITM is accredited in
accordance with the requirements of the standard NBN
EN ISO 15189:2007.
The questionnaire and the instructions were drafted in
Dutch. They were translated into French (both French and
Dutch are national languages in Belgium) by a native
French speaking professional and both versions were again
checked by a professional not involved in the study pre-
parations. Comments and feedback to the questionnaire
and instructions raised during the try-out session were
addressed during a next IPH referee committee meeting
and a final version of the questionnaire was approved.
Data analysis
Participants were asked to state the RDT brand they
used and to report their results in terms of observations
(i.e. the presence of control and test lines) and interpre-
tations. Interpretations referred to the final diagnosis:
participants were offered a free-text option and were
invited to submit their answer formulated as a report to
the clinician. Participants submitted the results on-line
via the IPH-EQA website or sent them by post mail to
IPH. The results were converted (answers through the
website) or encoded (forms sent by post mail) in an
Excel® database (Microsoft Corporation, Redmond,
Washington USA).
For analysis, the results of the RDT tests, and answers to
t h eq u e s t i o n n a i r ew e r er e v i e w e da n dg r o u p e d .A st h e
intended denominator consisted of the number of partici-
pants, only the first RDT was considered in case a partici-
pant used more than one RDT brand. Primarily, the
interpretations of RDT results (report to the clinician)
were considered. In case of an unexpected or incorrect
result, the observations (results of control and test lines)
were retrieved in order to distinguish between interpreta-
tive, analytical and clerical errors. In case a final result in
terms of interpretations was not clearly stated (e.g. phras-
ings such as “result depends on microscopy”), it was not
included for analysis. For interpretation and scoring of the
RDT results, major, minor and very minor errors were
defined based on relevance and impact on patient care,
they are as listed in Table 3. Continuous variables were
assessed for significance using the Student’st - t e s t .
Table 2 Overview of malaria RDT brands used by the participants (n = 128)
Manufacturer Malaria RDT Format Target antigens Numbers of
participants (%)
Inverness Medical Binax, Inc.,
Scarborough, Maine, USA
BinaxNOW® Malaria Test Card box Three-
band
HRP-2 + Aldolase 54 (42.1)
All Diag, Strasbourg, France Palutop+4® Cassette Four-band HRP-2 + Pv-pLDH +
pan-pLDH
26 (20.3)
DiaMed AG, Cressier s/Morat Switzerland OptiMal-IT Hybrid dipstick
Three-band
Pf-pLDH + pan-pLDH 23 (18.0)
Access Bio Inc, New Jersey, USA CareStart™ Malaria pLDH/HRP2
Combo test
Cassette Three-band HRP-2 + pan-pLDH 12 (9.4)
Standard Diagnostics Inc, Hagal-Dong,
Korea
SD Bioline Malaria Ag Pf/Pan FK
60
Cassette Three-band HRP-2 + pan-pLDH 11 (8.6)
Ultimed Ahrensburg, Germany Malaria (P. falciparum/pan) Test Cassette Three-band HRP-2 + pan-pLDH 1 (0.8)
Cypress Diagnostics, Leuven, Belgium Malaria Total Quick Test Cassette Three-band HRP-2 + pan-pLDH 1 (0.8)
The underlined names represent the shortened names used in the text to refer to the different RDT brands.
Table 3 Score for EQA test results, considered as “report
to the clinician”
Correct ￿ Correct diagnosis and correct report.
Very minor
error
￿ Not diagnosing or reporting the possibility of a mixed
infection, with non-falciparum species as the
disregarded species.
Minor error ￿ Missing the diagnosis of non-falciparum species.
￿ Reporting “positive” when information on
confirmation/ruling out of P. falciparum is available.
￿ Reporting P. vivax in stead of non-falciparum species.
￿ Correct result but with incorrect comment.
Major error ￿ Invalid RDT test result not recognized.
￿ Diagnosis of P. falciparum missed.
￿ P. falciparum diagnosed or reported as non-falciparum
species.
￿ Non-falciparum species diagnosed or reported as P.
falciparum.
￿ Negative sample diagnosed or reported as “positive”.
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In an attempt to explain for some RDT reporting errors,
the package inserts of the RDT kits were reviewed for
the “interpretation” section.
To have an idea about the expected parasite densities
of malaria samples in the present non-endemic setting,
the parasite densities of the samples processed at ITM
were retrieved. These samples were obtained from
patients attending the outpatient clinic at ITM or sent
by Belgian laboratories to ITM for confirmation in the
s c o p eo ft h en a t i o n a lr e f e r e n c ef u n c t i o n .O n l yt h ef i r s t
sample per patient was considered, for the period from
January 2000 to June 2010.
Results
EQA sessions
The try-out EQA session was performed on June 24
th,
2009, during summer season. Eight out of nine tempera-
ture monitored packages arrived at ITM. The median
duration of transport of the samples was 52 hours
(range 49 - 144 hours). Mean and maximum tempera-
tures during shipment were 23.6°C (ranges 22.6°C -
25.2°C) and 28.7°C (25.9°C - 32.1°C). The temperatures
during shipment had exceeded 25.0°C for a median
duration of 630 minutes (range 350 - 6,380 minutes).
The formal EQA session was organized on February
22
nd 2010, during winter season.
Results of the try-out testing were identical to those
obtained by RDT testing of fresh samples for the three
shipped samples and all the tested RDT brands. The
results of Cypress and Ultimed (performed on stored
samples at the time of the formal EQA session) were in
line with the expected results (HRP-2 and pan-pLDH
test lines visible in sample 1, no test lines visible in sam-
ple 2, and pan-pLDH line visible in sample 3).
An overview of participants and malaria RDTs used
The total number of laboratories subscribing to the
Belgian EQA “Microbiology” in 2009 - 2010 was 183. A
total of 128 subscribed to the session on malaria RDTs.
When surveyed, 50 of the 55 non-subscribing labora-
tories declared not to perform RDTs as part of malaria
diagnosis. In other words, 133/183 (72.7%) of clinical
laboratories offering malaria diagnosis were using RDTs
at the time of EQA, and 128 (96.2%) of them participated
to the present EQA session on malaria RDTs.
Table 2 lists the different RDT brands used by the 128
participants, matched with their format and target anti-
gens. Two participants used more than one RDT brand:
one of them used two additional brands (SD Bioline and
a P. vivax-pLDH specific RDT), and another participant
used Palutop as part of an internal evaluation procedure.
The results of these additional RDTs were not consid-
ered for analysis.
RDT results for the samples
Table 4 displays the results for sample 1 (P. falciparum,
parasite density of 53,024/μl). The expected result was:
“P. falciparum, a mixed infection with P. vivax, Plasmo-
dium ovale or Plasmodium malariae (or in case of the
four-band Palutop: “P. ovale or P. malariae“) cannot be
excluded”. Four participants did not give a final result in
terms of interpretation and report to the clinician. Their
observations of test lines were correct, but they were
not included for analysis. The final denominator con-
sisted of 124 participants. Only a single major error was
observed: one sample was reported as negative. How-
ever, the observations of test lines reported for this sam-
ple were correct (presence of HRP-2 and pan-pLDH
lines), suggesting an administrative error. Less than half
of the participants scored this sample correct. One third
committed the very minor error of not mentioning the
possibility of a mixed infection with non-falciparum
species. The reporting of only ‘positive’ without men-
tioning the presence of P. falciparum was observed in
16.9% of reports and was considered as a minor error.
Table 5 shows the result for sample 2 (no Plasmodium
detected). The expected result was “negative” or “no
Plasmodium antigen detected”. Three participants did
not answer a final result in terms of interpretation and
report to the clinician. Their observations of test lines
were correct, but they were not included for analysis.
The final denominator consisted of 125 participants.
Three major errors occurred. One participant reported
“P. falciparum or mixed infection”. The corresponding
observations of the test line results were supporting this
result, i.e. strong line intensities for both Pf-pLDH and
pan-pLDH lines. Two other participants reported the
Table 4 Results for sample 1: P. falciparum sample. Eligible answers of 124 participants were included
RDT brand
Reported result Binax Palutop Optimal CareStart SD Bioline Ultimed/Cypress Total (%)
Negative* 1 1 (0.8)
Positive
† 13 1 2 1 3 1 21 (16.9)
P. falciparum
‡ 1 22 10 7 4 44 (35.5)
P. falciparum or mixed infection 37 2 11 4 4 58 (46.8)
*major, † minor and ‡ very minor errors, see definitions in Table 3.
Gillet et al. Malaria Journal 2010, 9:359
http://www.malariajournal.com/content/9/1/359
Page 4 of 11absence of the control line for this sample but failed to
report the test result as invalid. Twenty-four participants
added a comment to the report: most comments were
valuable adjuncts pointing to the need of repeating the
RDT (and microscopy) in case of a negative test result
and a persistent suspicion of malaria. Four participants
added comments that were considered as not correct.
One of these comments was raised by two participants,
it stated - in case of negative result and persistent suspi-
cion - “to repeat the RDT at the next peak of fever”.
Table 6 displays the results of the third sample
(P. vivax, parasite density 3,251/μl). The expected
result was “P. vivax, P. ovale or P. malariae“ or “non-
falciparum malaria”. In case of the four-band Palutop
the correct result was: “P. vivax, mixed infection with
P. ovale and P. malariae not excluded”. Three partici-
pants did not answer a final result in terms of interpre-
tation and report to the clinician. Their observations of
test lines were correct, but they were not included for
analysis. The final denominator consisted of 125 partici-
pants. None of the participants using Binax observed a
test line and therefore all of them missed the expected
diagnosis. Minor errors observed were the reports of
simply “positive” or “pan-species” (n = 13, 10.5%), with-
out mentioning the absence of P. falciparum infection.
The report of “P. vivax“ in case of Palutop was consid-
ered a very minor error since the possibility of mixed
infection was not mentioned. In case of CareStart, the
answer “P. vivax“ was of note since this brand does not
include a P. vivax-specific test line.
Results of the questionnaire
Table 7 lists the numbers of requests for malaria diagnosis
processed by each laboratory in 2009, matched to the
number of laboratory staff. In line with the low number of
requests were the low numbers of RDT tests performed in
2009: 56.8% (71/125) of participants declared to have
processed 20 tests or less, another third (44/125, 35.2%)
mentioned between 20 and 100 RDTs. More than three
quarters of participants (97/120, 80.8%) replied that RDTs
had improved the diagnosis of malaria in their setting.
Table 8 lists the ease of use for each of the RDT
brands expressed on a scale from 0 to 10. Although the
median scores did not differ much and differences did
not reach statistical significance, there was a wider
range with a tendency to lower scores for Binax and, to
a lesser extent, OptiMAL.
Tables 9 and 10 list the diagnostic strategies during
and outside opening hours (weekend and night shifts).
A total of 125 participants gave eligible answers on their
diagnostic strategy during opening hours, among them
there were 113 participants who also offered malaria
diagnosis outside opening hours. Of note, five partici-
pants noted that they do not perform RDTs on follow-
up samples. The vast majority (95.2%) of participants
used RDTs as a complement or adjunct to microscopy
during opening hours, but only 62.8% did so outside
opening hours. Moreover, outside opening hours, 31.1%
of them relied on RDTs as the primary (4.4%) or the
single tool (25.7%) for malaria diagnosis. In a minority
(approximately 5%) of laboratories, the decision of
Table 5 Results for sample 2: Plasmodium negative sample. Eligible answers of 125 participants were included
RDT brand
Reported result Binax Palutop Optimal CareStart SD Bioline Ultimed/Cypress Total (%)
P. falciparum or mixed infection* 1 1 (0.8)
Absence of control line not reported as invalid* 1 1 2 (1.6)
Negative + comment which is NOT correct† 1 1 1 1 4 (3.2)
Negative + Correct comment 5 4 2 3 5 1 20 (16.0)
Negative 45 21 18 8 5 1 98 (78.4)
*major and † minor errors, see definitions in Table 3.
Table 6 Results for sample 3: P. vivax sample. Eligible answers of 124 participants were included
RDT brand
Reported result Reported result Binax Palutop Optimal CareStart SD Bioline Ultimed/Cypress Total (%)
Negative
† 51 51 (41.1)
Positive
† 1 1 2 1 5 (4.0)
Pan-species
† 1 2 2 3 8 (6.5)
P. vivax 23
‡ 5
† 28 (22.6)
P. vivax; P. ovale and P. malariae not excluded 2 2 (1.6)
Pan-species, not P. falciparum 20 4 6 30 (24.2)
*major, † minor and ‡ very minor errors, see definitions in Table 3.
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microscopy was left to the attending clinician.
Additional analyses
To generate an idea about the parasite densities of
patients presenting in Belgium and in the Grand Duchy
of Luxembourg, archived data were reviewed at ITM.
Table 11 lists the parasite densities of the samples sub-
mitted to ITM for each species, for a 10-year period
(January 2000 - June 2010).
The frequency of not reporting the possibility of a
mixed infection in the case of P. falciparum (sample 1,
35.3%) and P. vivax (22.6%, sample 3) was striking. In
sample 1, half of these errors occurred with Palutop and
represented the vast majority (22/26) of reports obtained
with this brand. For this reason, the package insert of
this kit was analysed: for the combination of the “Pf”
(HRP-2) and the “Pan” (pan-pLDH) lines, Palutop
instructions mentioned “P. falciparum“ without adding
the possibility of a mixed infection with P. ovale or
P. malariae. A similar omission was noted for the
P. vivax interpretation: the possibility of a co-infection
with P. malariae and P. ovale was not mentioned
(Figure 1). OptiMAL kit’si n s t r u c t i o n sn e i t h e rm e n -
tioned the possibility of a mixed infection in the case of
the diagnosis “P. falciparum“ (Figure 2).
Likewise, there were errors in the interpretation of test
lines in the CareStart package insert. From this brand,
two versions were available: a version with individually
wrapped tests ("Single Kits”, “Lab in a pack”)a n da
regular laboratory kit. For the interpretation of a single
pan-pLDH line, the former mentioned “pan-species”
and the latter “P. vivax”, thereby explaining for the
unexpected reporting of “P. vivax“ by five participants
(Figure 3, Table 6).
Discussion
The present study reports the findings of an EQA
session on malaria RDTs in a non-endemic setting.
Major analytical errors were rare. Minor errors occurred
frequently and were related to interpretation or report-
ing of test results (e.g. reporting “RDT positive” without
species identification when this was possible based on
RDT test line result). Errors in interpretations (e.g. the
possibility of mixed infections and the identification of
the non-falciparum species) were embedded in the
package insert instructions of some RDTs. Nearly half
(48.8%) of participants received ≤20 requests for malaria
diagnosis in 2009. During opening hours, 93.6% of parti-
cipants used RDTs as an adjunct to microscopy whereas
outside opening hours, nearly one third of them relied
on RDTs as primary or single tool for malaria diagnosis.
As far as known, this is the first report of an EQA on
malaria RDTs. It should be noted that the present EQA
session suffered from the weaknesses inherent to the
EQA method. For instance, only a few samples were
offered, precluding comparison of diagnostic characteris-
tics of the different RDT brands. Furthermore, partici-
pants were alerted to the importance of the samples and
probably might have devoted more attention to them
Table 7 Cross tabulation of the numbers of laboratory staff involved in malaria diagnosis versus the numbers of
requests for malaria diagnosis in 2009
Numbers of laboratory staff performing malaria diagnosis
Numbers of requests for malaria diagnosis in 2009 0-5 6-10 11-20 >20 Total
0-10 4 8 16 3 31
11-20 11 7 11 1 30
21-100 4 16 17 12 49
101-500 4 4 5 1 14
>500 11
Total 23 36 49 17 125
Table 8 Ease of use of the different malaria RDTs
expressed as a score
RDT
brand
Numbers of laboratories using this
brand
Median
Score
Range
Binax 52 8 2-10
OptiMAL 23 8 6-9
Palutop 25 9 7-10
CareStart 12 9 8-10
SD
Bioline
11 9 8-10
Table 9 Strategy of malaria diagnosis during opening
hours as reported by 125 participants
Diagnostic strategy of malaria during
opening hours
Numbers of
participants (%)
Microscopy + always RDT 99 (79.2)
Microscopy + RDT for confirmation 18 (14.4)
Microscopy + RDT if requested by the clinician 2 (1.6)
Microscopy and/or RDT, depending on the
request by the clinician
3 (2.4)
RDT, if positive or in case of doubt: +
microscopy
3 (2.4)
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E Q As e s s i o ns u c ha st h ep r e s e n to n ew i l lo n l yo f f e ra
cross sectional idea about the performances of the parti-
cipants. On the other hand, the method of EQA has its
strengths: it provides an educational stimulus to the par-
ticipants, allowing them to boost their self-confidence
and to show their credibility. Furthermore, EQA ses-
sions including the present one also provide information
to the health authorities: they provide insights into the
participants’ performance levels, may trace problems in
test kits and methods and they can survey the use of
diagnostic algorithms [21]. A particular strength of the
present EQA was its representativeness: in Belgium, sub-
scription to EQA sessions is mandatory for clinical
laboratories and the registration fee covers all sessions.
This particular condition explains for the high coverage
rate (96.2% of all laboratories performing RDTs) of this
EQA session.
The try-out EQA session validated the use of clinical
samples after storage and shipment. According to WHO
findings, antigen stability in sample panels is preserved
during storage at -70°C for 20 months; in addition, sto-
rage at 4°C before freezing samples does not impair
panel quality nor does storage at room temperature for
up to 60 days [22]. In light of these findings and the
present results, extension of EQA sessions to other set-
t i n g ss u c ha se n d e m i cf i e l ds e t t i n g sm i g h tb ef e a s i b l e .
T h eo n l yd i f f e r e n c ew i t hf r e s hc l i n i c a ls a m p l e si st h e
hemolysis caused by freezing: the additional hemolysis
however does not interfere with RDT processing but
contributes to swift clearance of the background on the
nitrocellulose strip [23].
In the present EQA session, analytical errors were
rare. Two major errors were observed. The single
missed diagnosis of P. falciparum (sample 1) was related
to an administrative rather than to an analytical error;
the unexpected single “P. falciparum“ report for one out
of 26 Palutop tests (sample 2) might also be related to a
clerical error (mixing up specimens or laboratory forms)
although the reported test line results were in line with
the correct result. More of concern was the missed
interpretation of invalid test results by two participants,
which was considered as a major error: in the absence
of a visible control line, test results are not reliable and
the test should be repeated. Invalid test results occur
rarely (<0.5% of samples tested) but consistently [24-27]
and laboratory staff should be alert to this phenomenon.
Interpretation or reporting of RDT results was more
subject to errors: simply reporting “positive” without
mentioning the species in the case of P. falciparum
(Sample 1, 16.9%) and non-falciparum (Sample 3, 4.0%)
or reporting “pan-species” without mentioning that
P. falciparum was not involved (Sample 3, 6.5%) was
Table 10 Strategy of malaria diagnosis outside opening
hours as reported by 113 participants
Diagnostic strategy of malaria outside
opening hours
Numbers of
participants (%)
Microscopy + always RDT 63 (55.8)
Microscopy + RDT for confirmation 8 (7.1)
Microscopy + RDT if requested by the clinician 2 (1.8)
Microscopy alone 2 (1.8)
Microscopy and/or RDT, depending on the
request by the clinician
3 (2.7)
RDT: if RDT positive, microscopy is done
instantly; if RDT is negative, microscopy is done
the next day
5 (4.4)
RDT + microscopy next day 1 (0.9)
RDT: if positive or in case of doubt: +
microscopy
16 (14.2)
RDT alone, no microscopy 13 (11.5)
Table 11 Distribution of parasite densities (asexual parasites/μl) per species for the 1066 Plasmodium positive samples
submitted to ITM for the period January 2000 - June 2010. (Only the first sample per patient was included)
Parasite density Single infection, species Mixed infection
†
Numbers P. falciparum P. vivax P. ovale P. malariae
0-100 81 3 12 3 0
101-500 93 14 22 3 2
501-5,000 221 52 38 20 4
5,001-250,000 360 59 14 6 5
>250,000 53 1
Total. 808 129 86 32 11
Cumulative (%)
≤100 10.0 2.3 14.0 9.4 0
>100 90.0 97.7 86.0 90.6 100
>500 78.5 86.8 60.5 81.3 81.8
>5.000 51.1 46.5 16.3 18.8 45.5
>250.000 6.6 0.01 0 0 0
† Mixed infections included P. falciparum infection with P. ovale (n = 4) or P. malariae (n = 5) and P. malariae infection with P. ovale (n = 1) or P. vivax (n = 1).
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f r o mt h eR D Tr e s u l t s ,i np a r t i c u l a rt h ep r e s e n c eo r
absence of the potentially fatal P. falciparum, should be
exploited.
Sample 2 did not contain Plasmodium antigen.
Although this was a confirmed malaria-negative sample
correctly identified by 97.6% of participants, it should be
noted that false-negative RDT results may occur. Rea-
sons for false-negative RDT results in a non-endemic
setting are low parasite densities, polymorphisms in
HRP-2 and the prozone effect. Low parasite densities
are by far the most frequent cause of false-negative
RDTs: for P. falciparum, they occur more frequently
below the threshold of 100 parasites/μl ,b u ta tt h i s
density non-immune travelers can present with symp-
toms [19,26-29]. From Table 11 can be read that P. falci-
parum samples with parasite densities below 100/μlc a n
be expected in about 10% of samples. In such cases - and
as raised by some participants as a comment to their
report of sample 2 - repeated testing after 8 - 12 hours is
advised, for up to four consecutive samplings [30,31]. Of
note, the comment of awaiting a next peak of fever for
repeating the RDT was considered as a minor error:
although there are variations in antigen production
during the cycle, there is no clear relation between the
concentration of antigens and any particular moment of
the cycle, yet the peak of fever [29] and a periodic fever
pattern does not occur in most of the P. falciparum
Figure 2 Package insert of OptiMAL, test interpretation. The instructions do not mention the possibility of a mixed infection in case of
“Positive for P. falciparum“.
Figure 1 Package insert of Palutop, test interpretation. The instructions do not mention the possibility of a mixed infection in case of “P.
falciparum malaria” and “P. vivax malaria”.
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Page 8 of 11infections. Polymorphisms in HRP-2 may give rise
to variations that are less likely to be picked up by
current RDTs; they are geographically confined to the
Asia-Pacific and South-American regions [32-34]. For the
prozone effect, high antigen concentrations block all
available binding sites of both the detection and the
capture antibodies, thereby hindering test line generation.
It occurs at high parasite densities of P. falciparum and
presents mostly as test lines with spuriously low intensity,
although complete negative r e s u l t sd oo c c u r .I tt e n d st o
occur in HRP-2 based but not in Pf-pLDH based
tests [35].
The failure of Binax to detect P. vivax in sample 3 was
not considered as a major error in light of the ability of
RDTs to detect non-falciparum species. In addition,
EQA sessions are not designed as a side-to-side compar-
ison of different brands nor as an evaluation of RDT test
characteristics. However, it demonstrates the lower
sensitivity of RDTs to detect non-falciparum species as
compared to the detection of P. falciparum [19,26-29,36].
For Binax (in its most recent generation), compiled sensi-
tivity for the diagnosis of P. vivax has been calculated to
be 68.9% [29]. In a population of returned travelers,
Binax displayed sensitivities of 86.7% for pure P. vivax
samples [30]. In comparison, OptiMAL which was run
side-to-side in the latter study displayed a higher sensitiv-
ity for P. vivax (91.0%), at the expense of a lower sensitiv-
ity for P. falciparum.C h a l l e n g e dt oap a n e lo fs t o r e d
samples at ITM, SD Bioline, Palutop and CareStart
showed overall sensitivities for the detection of P. vivax
of 87.5%, 66.0% and 77.6% respectively [19,26,28], with,
as for Binax in the current sample, false-negatives
not limited to low parasite densities. For P. ovale and
P. malariae, reported sensitivities have been even lower
[19,26,28,36]. As for P. falciparum, the sensitivity for the
non-falciparum species is related to parasite density, with
at h r e s h o l dv a l u ea t5 0 0 / μl [19,24-26,28] or even at
5,000/μl [12] but false negatives also occur above these
densities. Parasite densities below these 500 and 5,000
threshold values occur in 23.0% and 67.6% of the non-
falciparum samples in the Belgian reference laboratory
for malaria (Table 11).
Not reporting the possibility of a mixed infection of
P. falciparum with non-falciparum species (Sample 1,
35.5%) was considered a minor error, as this has no
impact on the short-term patient care: in case of an addi-
tional P. vivax or P. ovale species, the persistent liver
schizonts have to be eradicated with primaquine treat-
ment, but there is time to await this information from
the reference laboratory. However, it was striking that
this error as well as the error of not reporting the possibi-
lity of mixed infections in the case of P. vivax (sample 3,
22.6%) were embedded in the package insert instructions
of Palutop and OptiMAL. Likewise there were errors on
interpretation in the Carestart package insert instruc-
tions, with incorrect labeling of the test lines in both
versions. Manufacturers should be encouraged to revise
and adapt their instructions where needed, especially
with regard to test line interpretations.
The questionnaire confirmed the low critical volume
in terms of requests for malaria diagnosis: assuming a
5-10% positivity rate for patients suspected of malaria, it
is clear that laboratory technicians have little exposure
to malaria-positive slides.E v e ni nt h o s el a b o r a t o r i e s
with high numbers of requests, the number of perfor-
mances per technician will be reduced by a high number
of laboratory staff participating in the diagnosis. This is
comparable to the situation in other countries, with
about half of laboratories in the U.K. carrying out less
than 100 malaria requests each year and about 10% of
laboratories fewer than 10 [18]. In France, about 60% of
3,300 surveyed laboratories declared to have seen a
malaria case the previous year, and only 5% made the
diagnosis of malaria five times or more yearly [37].
The number of participants (80.8%) replying that
malaria RDTs had improved the diagnosis of malaria
in their setting was much higher than revealed by a sur-
vey in the UK (12.6% out of 305 respondents stated
that RDTs had revised their malaria diagnosis) [18].
Although the meaning and phrasing of the latter
question were different ("revised” versus “improved”),
the difference in numbers is striking. It may be attribu-
ted to a growing experience with malaria RDTs in clini-
cal laboratories.
The wider range with a tendency to lower scores for
ease of use for Binax and, to a lesser extent, OptiMAL
m a yb ee x p l a i n e db yt h ef a c tt h a tt h e s ek i t si n c l u d e
more steps than the more recently released one-step
kits such as CareStart and SD Bioline. In ITM experi-
ence as well as that of others [7,38], particular problems
can arise with the use of the transfer device: without
having processed high numbers of samples, it may be
difficult to master the RDT kit’s loops, straws or
capillary tubes, which are frequently small and not user-
friendly. The volume of blood used to run the test is cri-
tical: an excess of blood may increase the risk and/or
Figure 3 Package insert of CareStart “Single Kit”. Test
interpretation stating “P. vivax“ instead of “non-falciparum species”
when a single pan-pLDH line is visible.
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due to a bad clearance of the strip, while a shortage of
blood may decrease the sensitivity of the test.
Of particular interest are the diagnostic strategies
during and outside opening hours. Whereas the vast
majority of participants used RDTs as a complement or
adjunct to microscopy during opening hours, the reli-
ance on RDTs as the primary or the single diagnostic
tool during night and weekend shifts is of concern. In
the UK-survey of 2006 a similar tendency was observed:
less than 5% of 327 surveyed laboratories used exclu-
sively a RDT during opening hours, versus 15-20% out-
side opening hours [18]. The extent of the potential
risks as a result of this strategy may be serious especially
since, according to a survey in Portugal, about half of
the requests for the diagnosis of malaria arrive outside
opening hours, accounting for 60% of the diagnoses
[39]. In view of their strengths, RDTs are a valuable
a d j u n c tf o rm a l a r i ad i a g n o s i sa n ds h o u l d-i nt h e
authors’ opinion - be used together with microscopy in
all cases of malaria suspicion in non-endemic settings.
Conversely, RDT limitations do not justify them as the
unique tool for diagnosis in non-endemic settings:
microscopy is needed to recover diagnosis that may be
missed by RDTs (prozone effect, non-falciparum species
and low parasite densities), and also to assess signs of
severity (elevated parasite densities and the presence of
schizonts and haemozoin in the case of P. falciparum).
It is important to ascertain reliable diagnosis of malaria
during and outside office hours, and competent micro-
scopy should be in reach at all times. To minimize the
risk of microscopy errors and as an in-service training
and feedback, all positive and doubtful samples should
be submitted to the malaria reference laboratory.
T h ep o l i c yo fl e a v i n gt h ed ecision on the choice of
RDT versus microscopy to the attending clinician may
result in not performing the RDT (thereby not exploit-
ing possible information generated by the RDT) or not
performing microscopy. This policy is probably related
to the reimbursement system of medical costs in
Belgium: national health insurance reimburses only
laboratory analyses that are explicitly requested by the
clinician. Hospital-based diagnostic and treatment algo-
rithms can guide the choice and priorities of laboratory
tests, but for the individual patient however, the ulti-
mate request of RDT, microscopy or both depends on
the clinician’s decision.
The additional comment of five participants that they
do not perform RDTs on follow-up samples is a correct
policy. Indeed, HRP-2 may persist in the circulation for
up to several weeks. Aldolase and pLDH depend on the
living parasites and they rapidly decline after start of
correct treatment, but their use is limited because they
are also expressed by gametocytes [40]. Consequently,
monitoring of treatment efficacy should be done by
microscopy only.
Conclusion
From the present EQA session, it is clear that RDTs are
an essential part of malaria diagnosis in most diagnostic
laboratories in Belgium and the Grand Duchy of Luxem-
bourg. According to the results of the present EQA, it
can be concluded that analytical errors in the perfor-
mance of RDTs are rare. Errors are mainly related to
the interpretation and reporting of RDT results, partly
due to errors in the package insert. Laboratory staff has
limited exposure to malaria positive samples in this
non-endemic setting. Whereas during opening hours,
RDTs are used as a complement or adjunct to micro-
scopy, there are about one third of participants that rely
on RDTs as the primary or the single diagnostic tool
outside opening hours, which should be avoided.
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